Abstract
In addition to well-established genetic abnormalities -particularly gene mutations, deletions or translocations -, epigenetic abnormalities are also implicated in the development and progression of hematological malignancies. As such, the constitutive pattern of DNA methylation and histone acetylation observed in normal hematopoietic cells is remarkably altered in both myeloid and lymphoid tumors. Recent advances in the understanding of these transcriptional and post-transcriptional mechanisms in normal B and T cells as well as malignant lymphoid cells have been instrumental in the development of novel diagnostic markers, prognostic classification and targeted therapeutic approaches. This review focuses on the most important epigenetic alterations discovered in lymphoma-derived cell lines and primary lymphoid tumors and how pharmacologic manipulation of these abnormalities could eventually change the way we treat them in the clinic.
Keywords: DNA methylation, Histone acetylation, Demethylating agents, Histone deacetylase inhibitors, Non-Hodgkin's lymphoma, Hodgkin's lymphoma, Chronic lymphocytic leukemia
Current Cancer Drug Targets
Title: Novel Epigenetic Targets in Lymphoproliferative Disorders
Volume: 8 Issue: 5
Author(s): Julio Delgado
Affiliation:
Keywords: DNA methylation, Histone acetylation, Demethylating agents, Histone deacetylase inhibitors, Non-Hodgkin's lymphoma, Hodgkin's lymphoma, Chronic lymphocytic leukemia
Abstract: In addition to well-established genetic abnormalities -particularly gene mutations, deletions or translocations -, epigenetic abnormalities are also implicated in the development and progression of hematological malignancies. As such, the constitutive pattern of DNA methylation and histone acetylation observed in normal hematopoietic cells is remarkably altered in both myeloid and lymphoid tumors. Recent advances in the understanding of these transcriptional and post-transcriptional mechanisms in normal B and T cells as well as malignant lymphoid cells have been instrumental in the development of novel diagnostic markers, prognostic classification and targeted therapeutic approaches. This review focuses on the most important epigenetic alterations discovered in lymphoma-derived cell lines and primary lymphoid tumors and how pharmacologic manipulation of these abnormalities could eventually change the way we treat them in the clinic.
Export Options
About this article
Cite this article as:
Delgado Julio, Novel Epigenetic Targets in Lymphoproliferative Disorders, Current Cancer Drug Targets 2008; 8 (5) . https://dx.doi.org/10.2174/156800908785133222
DOI https://dx.doi.org/10.2174/156800908785133222 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
AKT-pathway Inhibition in Chronic Lymphocytic Leukemia Reveals Response Relationships Defined by TCL1
Current Cancer Drug Targets Immune Therapy in Pancreatic Cancer: Now and the Future?
Reviews on Recent Clinical Trials The Potential of PI3K/AKT/mTOR Signaling as a Druggable Target for Endometrial and Ovarian Carcinomas
Current Drug Targets Antiangiogenic Therapy
Current Pharmaceutical Design Targeting Metabolic Enzymes in Cancer – Clinical Trials Update
Current Enzyme Inhibition Clinical Pharmacogenetics and Potential Application in Personalized Medicine
Current Drug Metabolism Recombinant Antibodies in Cancer Therapy
Current Protein & Peptide Science Targeting Receptor Tyrosine Kinases Using Monoclonal Antibodies: The Most Specific Tools for Targeted-Based Cancer Therapy
Current Drug Targets Resveratrol as an Enhancer of Apoptosis in Cancer: A Mechanistic Review
Anti-Cancer Agents in Medicinal Chemistry The Coordinated Role of CYP450 Enzymes and P-gp in Determining Cancer Resistance to Chemotherapy
Current Drug Metabolism Electroporation Gene Therapy Preclinical and Clinical Trials for Melanoma
Current Gene Therapy The Bcl10 / Malt1 Signaling Pathway as a Drug Target in Lymphoma
Current Drug Targets Yin and Yang of Polyphenols in Cancer Prevention: A Short Review
Anti-Cancer Agents in Medicinal Chemistry Artificial O2 Carriers: Status in 2005
Current Pharmaceutical Design AKT: A Potential Target for Thyroid Cancer Therapy
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Defective Autophagy in Fibroblasts May Contribute to Fibrogenesis in Autoimmune Processes
Current Pharmaceutical Design Bugs and Drugs: Oncolytic Virotherapy in Combination with Chemotherapy
Current Pharmaceutical Biotechnology Bladder Cancer Stem Cells
Current Stem Cell Research & Therapy Denosumab: The Era of Targeted Therapies in Bone Metastatic Diseases
Current Cancer Drug Targets Current Advances in the Development of Anticancer Drugs Targeting Tyrosine Kinases of the Src Family
Current Drug Therapy